Annovis Granted US Patent for Buntanetap in Neurological Injury Prevention and Treatment

Annovis has secured a US patent for buntanetap, a treatment for neurological injuries caused by brain infections. The company's rating has been upgraded to "super" by Bloomberg, based on its valuation, earnings revisions, and visibility. The patent is a significant milestone for Annovis, which aims to develop treatments for neurological disorders. The company's rating reflects its strong fundamentals, valuation, and financial estimates revisions, making it a promising investment opportunity.